CHARLES RIVER LABORATORIES INTERNATIONAL INC
S-1/A, EX-27.1, 2000-06-23
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Previous: CHARLES RIVER LABORATORIES INTERNATIONAL INC, S-1/A, EX-23.2, 2000-06-23
Next: CHARLES RIVER LABORATORIES INTERNATIONAL INC, S-1MEF, 2000-06-23



<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<LEGEND>
THE SCHEDULE CONTAINS SUMMARY INFORMATION EXTRACTED FROM THE CONSOLIDATED
STATEMENT OF EARNINGS FOR THE YEAR ENDED DECEMBER 25, 1999 AND THE CONSOLIDATED
BALANCE SHEET AT DECEMBER 25, 1999 AND IS QUALIFIED IN ITS ENTIRETY BY
REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<CIK> 0001100682
<NAME> CHARLES RIVER LABORATORIES HOLDINGS, INC.
<MULTIPLIER> 1,000

<S>                             <C>                     <C>                     <C>                     <C>
<C>
<PERIOD-TYPE>                   12-MOS                   12-MOS                   12-MOS                   12-MOS
12-MOS
<FISCAL-YEAR-END>                          DEC-28-1996             DEC-27-1997             DEC-26-1998             DEC-26-1998
             DEC-25-1999
<PERIOD-END>                               DEC-28-1996             DEC-27-1997             DEC-26-1998             SEP-26-1998
             SEP-25-1999
<CASH>                                               0                  17,915                  24,811                       0
                   3,457
<SECURITIES>                                         0                       0                       0                       0
                       0
<RECEIVABLES>                                        0                  28,200                  32,466                       0
                  33,820
<ALLOWANCES>                                         0                     688                     898                       0
                     854
<INVENTORY>                                          0                  28,904                  30,731                       0
                  28,577
<CURRENT-ASSETS>                                     0                  83,323                  97,214                       0
                  77,303
<PP&E>                                               0                  76,889                  82,690                       0
                  79,349
<DEPRECIATION>                                       0                   8,320                   9,168                       0
                       0
<TOTAL-ASSETS>                                       0                 196,211                 233,410                       0
                 210,371
<CURRENT-LIABILITIES>                                0                  41,577                  59,792                       0
                  56,707
<BONDS>                                              0                       0                       0                       0
                       0
                                0                       0                       0                       0
                       0
                                          0                       0                       0                       0
                       0
<COMMON>                                             0                       1                       1                       0
                       1
<OTHER-SE>                                           0                  17,836                  17,836                       0
                  17,836
<TOTAL-LIABILITY-AND-EQUITY>                         0                 196,211                 233,410                       0
                 210,371
<SALES>                                        155,604                 170,713                 193,301                 145,519
                 161,096
<TOTAL-REVENUES>                               155,604                 170,713                 193,301                 145,519
                 161,096
<CGS>                                           97,777                 111,460                 122,547                  91,041
                  97,230
<TOTAL-COSTS>                                   97,777                 111,460                 122,547                  91,041
                  97,230
<OTHER-EXPENSES>                                33,685                  37,177                  35,429                  26,238
                  30,528
<LOSS-PROVISION>                                     0                       0                       0                       0
                       0
<INTEREST-EXPENSE>                                 491                     501                     421                     311
                     307
<INCOME-PRETAX>                                 15,245                  15,340                  23,378                  18,459
                  19,952
<INCOME-TAX>                                    10,889                   8,449                  14,123                  11,280
                  16,903
<INCOME-CONTINUING>                             15,245                  15,340                  23,378                  28,459
                  19,952
<DISCONTINUED>                                       0                       0                       0                       0
                       0
<EXTRAORDINARY>                                      0                       0                       0                       0
                       0
<CHANGES>                                            0                       0                       0                       0
                       0
<NET-INCOME>                                    15,245                  15,340                  23,378                  28,459
                  19,952

<EPS-BASIC>                                          0<F1>                       0<F1>         0<F1>         0<F1>

                       0<F1>
<EPS-DILUTED>                                        0<F1>                       0<F1>         0<F1>         0<F1>
                       0<F1>
<FN>
<F1>The Company's equity is not publicly stated.
</FN>


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission